plasminogen receptor with a C-terminal lysineGenealiases: AD025 · C9orf46 · MDS030 · PLG-RKT · Plg-R(KT)
Q-omics provides the consensus-scored PLGRKT profile across patient tissues and cancer cell-line models. PLGRKT expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PLGRKT is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, PLGRKT protein abundance shows 20,121 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRP, KIRC, and PDAC as cancer lineages where PLGRKT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLGRKT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLGRKT survival associations across molecular data types. PLGRKT RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLGRKT RNA expression–survival associations across cancer types. High PLGRKT expression shows unfavorable associations in UVM and HNSC, but favorable associations in KIRP, BRCA, OV and COAD. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PLGRKT RNA expression.
This table summarizes PLGRKT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PLGRKT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLGRKT shows lower tumor expression in KIRC and KICH and higher tumor expression in LIHC, BRCA, LUAD and BLCA. The KIRC box plot shows higher PLGRKT RNA expression in normal versus tumor tissue (log2 FC = −0.783, t-test p < 0.001).
This table shows molecular features associated with PLGRKT in patient tissues and cancer cell lines. In patient samples, PLGRKT shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, PLGRKT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
